APAC Colorectal Cancer Screening Market Industry Trends and Forecast to 2034: Segmented by (Test, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$1.81 BnPlaceholder estimate
Estimate 2025$1.96 Bn22.8% of the global market
Projected 2034$3.92 Bn 99.9%Adds $1.96 Bn over 9 forecast years
CAGR 2025–20348.0%Faster than 25% of 186 Medical Devices markets here
Exact Sciences Corporation, Guardant Health, Inc., Olympus Corporation, Quidel Corporation, Eiken Chemical and 1 more (see all)
Active clinical trials
22 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Colorectal Cancer Screening Market Analysis Executive Summary
Colorectal cancer screening finds bowel cancer and pre-cancer early, using stool tests, blood tests and colonoscopy.
Key segments of the colorectal Cancer Screening market include test (Stool DNA Tests, FIT Tests and Blood-Based Tests) and setting (At-Home, Clinics and Hospitals).
Asia Pacific Colorectal Cancer Screening market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Colorectal Cancer Screening Market Dynamics
Market Growth Drivers
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the colorectal Cancer Screening market. Faster approvals and new combinations are improving survival.
Opportunity
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the colorectal Cancer Screening market.
Market Restraints
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the colorectal Cancer Screening market, especially in low- and middle-income countries.
Competitive Landscape for Colorectal Cancer Screening Market in APAC
The colorectal Cancer Screening market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Colorectal Cancer Screening Market in APAC
Colorectal Cancer Screening in APAC: rules, payment and research
In some of the countries we cover here, medical devices are regulated by TGA (Australia)[1], NMPA (China)[2], MDACS (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], MDA (Malaysia)[6], Medsafe (WAND) (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9], Thai FDA (Thailand)[10], Ministry of Health (Indonesia)[11], DRAP (Pakistan)[12], MFDS (South Korea)[13] and Ministry of Health (Vietnam)[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[15], basic medical insurance (China)[16], the Hospital Authority (Hong Kong)[17], Ayushman Bharat PM-JAY (India)[18], public health insurance (Japan)[19], subsidised public care (Malaysia)[20], Pharmac (New Zealand)[21], PhilHealth (Philippines)[22], MediShield Life (Singapore)[23], the Universal Coverage Scheme (Thailand)[24], JKN (BPJS Kesehatan) (Indonesia)[25], out of pocket and Sehat Sahulat (Pakistan)[26], National Health Insurance (South Korea)[27] and social health insurance (Vietnam)[28]. ClinicalTrials.gov lists 22 studies on Colorectal Cancer Screening that are recruiting, active or about to start in APAC.[29]
[29]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how colorectal Cancer Screening products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Test
4.2 By Setting
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Exact Sciences
7.2 Guardant Health
7.3 Olympus Corporation
7.4 QuidelOrtho
7.5 Eiken Chemical
7.6 Fujifilm
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The colorectal Cancer Screening market can be segmented based on various criteria, including test, setting and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Colorectal Cancer Screening right now, from free public sources.
Clinical trials
22 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Colorectal Cancer Screening market in Asia Pacific?
Placeholder estimate: about $1.96 Bn in 2025, rising to about $3.92 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Colorectal Cancer Screening market in Asia Pacific growing?
Placeholder estimate: about 8.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Colorectal Cancer Screening market report cover?
The report splits the market by test (Stool DNA Tests, FIT Tests, Blood-Based Tests, Colonoscopy and more), setting (At-Home, Clinics, Hospitals) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Colorectal Cancer Screening market?
Key players include Exact Sciences Corporation, Guardant Health, Inc., Olympus Corporation, Quidel Corporation, Eiken Chemical and FUJIFILM Holdings Corporation.
What is driving the Colorectal Cancer Screening market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the colorectal Cancer Screening market. Faster approvals and new combinations are improving survival.
How many clinical trials on Colorectal Cancer Screening are running in Asia Pacific?
22 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Colorectal Cancer Screening?
PubMed lists 3,251 papers on Colorectal Cancer Screening added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.